A Clinical trial to study the effect of the Drug Maampisin Chooranam in patients having excessive and prolonged menstrual bleeding (Menorrhagia)

An Open Non-Randomized Clinical trial of Maampisin Chooranam in Pitha Perumbadu (Menorrhagia)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012381

Enrollment

Registered

2018-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- FEMALE WITH EXCESSIVE AND PROLONGED MENSTRUATION

Interventions

Intervention1: MAAMPISIN CHOORANAM: 2 Grams of Maampisin Chooranam is administrated trice a day with honey for 3 consecutive cycles Control Intervention1: NIL: NIL Control Intervention2: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Age 15 to 50 years Willing to participate in trial and signing in consent proforma complaints of excessive and prolonged menstruation Perimenopausal Menorrhagia Puberty Menorrhagia Anaemia due to Menorrhagia Menorrhagia in PCOD

Exclusion criteria

Exclusion criteria: Fibroid polyp Chocolate cysts Ovarian feminizing tumour Hypothyroidism Bleeding disorders Patients having IUCD Uterine fibroid Adenomyosis Abortion and Pregnancy

Design outcomes

Primary

Measure	Time frame
Outcome is mainly assessed by reduction in clinical symptoms and by comparing the following parameters before and after treatment. Reduced amount of blood flow is assessed by number of sanitary pads used before and after treatment. Timepoint: 48 days	—

Secondary

Measure	Time frame
Secondary outcome is assessed by comparing the safety parameters before and after treatmentTimepoint: 48 days	—

Countries

India

Contacts

Public ContactDr Dhivyabharathi A

Government Siddha Medical College

drkkanakavalli@gmail.com9444122865

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026